Neue Studien: Europe PMChttps://www.psoriasis-news.de/articles.html/1_articles/page/13/?d=1Neue Studien: Europe PMCdeToward precision in psoriatic arthritis: addressing the challenge of difficult-to-treat disease.https://www.psoriasis-news.de/articles.html/1_articles/toward-precision-in-psoriatic-arthritis-addressing-the-challenge-of-difficult-to-treat-disease-r259/IntroductionDifficult-to-treat psoriatic arthritis (D2T-PsA) is increasingly recognized as a complex clinical entity characterized by persistent disease burden despite multiple targeted therapies. Its identification is essential to improve patient outcomes and to guide the development of new therapeutic strategies.

Areas covered

In this perspective article, we discuss the evolving concept of D2T-PsA, including its epidemiology, clinical characterization, and underlying pathophysiological mechanisms. We highlight the role of gender differences, psychosocial comorbidities, and central sensitization in shaping disease persistence and patient-reported impact. We also examine the limitations of current disease activity indices (DAPSA, PsAID, PASDAS) in capturing heterogeneity and the need for multidimensional frameworks. A structured literature search was conducted in PubMed/MEDLINE and Scopus databases (January 2020-June 2025), restricted to English-language publications, using combinations of the terms psoriatic arthritis, difficult-to-treat, refractory, and difficult-to-manage. Additional references were identified from conference abstracts and relevant bibliographies.

Expert opinion

Recognizing D2T-PsA as a distinct, multifactorial entity is critical to advancing personalized medicine. Future directions will involve harmonizing EULAR and GRAPPA frameworks, integrating biomarker discovery, digital tools, and adaptive trial designs, and embedding patient perspectives. This multidimensional approach is expected to transform treatment from empirical cycling toward precision care in psoriatic arthritis.

Weiterlesen

]]>259Tue, 14 Oct 2025 14:32:50 +0000Efficacy and safety of gut microbiota-targeted therapy in patients with psoriasis: a systematic review and meta-analysis of randomized controlled trials.https://www.psoriasis-news.de/articles.html/1_articles/efficacy-and-safety-of-gut-microbiota-targeted-therapy-in-patients-with-psoriasis-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials-r254/No abstract supplied.

Weiterlesen

]]>254Fri, 10 Oct 2025 06:15:28 +0000Preterm birth in women with psoriatic arthritis: what are the risks and risk factors? A collaborative cohort study from Sweden, Denmark and Norway.https://www.psoriasis-news.de/articles.html/1_articles/preterm-birth-in-women-with-psoriatic-arthritis-what-are-the-risks-and-risk-factors-a-collaborative-cohort-study-from-sweden-denmark-and-norway-r253/ObjectiveTo estimate risk and to identify risk factors for preterm birth in pregnant women with psoriatic arthritis (PsA) in relation to maternal characteristics, treatment and disease activity, both before and during pregnancy.

Methods

We linked clinical rheumatology registers to medical birth registers in Sweden, Denmark and Norway and identified PsA pregnancies and control pregnancies 2006-2021, matched 1:10 on age, parity, country and birth year. Adjusted ORs (aORs) for preterm birth in PsA pregnancies vs control pregnancies were calculated overall and stratified by maternal characteristics, antirheumatic treatment and disease load (9 months before and during pregnancy).

Results

We observed 54 preterm births among 688 PsA pregnancies (7.8%) versus 312 among 6880 control pregnancies (4.5%); aOR, 95% CI: 1.80, 1.29 to 2.51. The risk estimate was largely unaffected by parity, smoking and body mass index. PsA pregnancies exposed to a combination of biologic and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and/or glucocorticoids during pregnancy had a markedly increased risk of preterm birth compared with control pregnancies (4.44, 2.07 to 9.50), whereas exposure to biological DMARD (bDMARD) monotherapy (primarily tumour necrosis factor inhibitors) had not (0.73, 0.22 to 2.42). High disease load before pregnancy was associated with increased risk. The proportion of preterm birth was higher in those stopping bDMARD during the first trimester (21%) opposed to those continuing past the first trimester (10%) based on few events.

Conclusion

We identified an 80% increased risk of preterm birth in PsA pregnancies compared with control pregnancies. Antirheumatic combination therapy during and high disease load before pregnancy constituted risk factors. Discontinuing bDMARD treatment in early pregnancy further increased the risk. Our findings support that a subgroup of PsA pregnancies should be considered high-risk pregnancies.

Weiterlesen

]]>253Fri, 10 Oct 2025 06:15:28 +0000Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China.https://www.psoriasis-news.de/articles.html/1_articles/cost-effectiveness-of-deucravacitinib-versus-apremilast-of-moderate-to-severe-plaque-psoriasis-in-china-r252/ObjectivesThe study aimed to assess the cost-effectiveness of deucravacitinib versus apremilast for treating moderate-to-severe plaque psoriasis from the Chinese healthcare system's perspective.

Methods

The treatment efficacy of deucravacitinib was compared with apremilast using response rates derived from the head-to-head phase 3 clinical trials, POETYK PSO-1 and PSO-2. A decision-tree (first 24-week)/ Markov model (later period) was constructed to estimate the incremental cost per quality-adjusted life-year (QALY) gained over a lifetime horizon. The efficacy inputs were based on randomized controlled trials, while adverse event rates, discontinuation probabilities, costs, and utility data were obtained from relevant literature and Chinese sources. A 5% annual discount rate was used for the analysis of outcomes and costs. Model outcomes were characterized by quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER). One-way sensitivity analysis and probability sensitivity analysis (PSA) were performed to examine the robustness of the results.

Results

According to the assumed lifetime horizon and model, the ICER of deucravacitinib 6 mg once daily compared with apremilast 30 mg twice daily was 140,047 CNY per QALY. Deucravacitinib was more cost-effective than apremilast at the willingness-to-pay (WTP) threshold of 287,247 CNY per QALY. In the One-way sensitivity analysis, the cost of deucravacitinib was identified as the parameter exerting the greatest impact on the base-case results. The results of PSA showed the probability of deucravacitinib being cost-effective was 99.4%.

Conclusion

At the WTP threshold of 287,247 CNY, deucravacitinib 6 mg once daily was a cost-effective treatment strategy for moderate-to-severe plaque psoriasis compared with apremilast 30 mg twice daily from the Chinese healthcare system perspective over a lifetime horizon.

Weiterlesen

]]>252Fri, 10 Oct 2025 06:15:28 +0000Psoriasis Increases the Risk of ANCA Associated Vasculitis: Insights from A Propensity Score-Matched Study.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-increases-the-risk-of-anca-associated-vasculitis-insights-from-a-propensity-score-matched-study-r251/PurposeThis study aimed to investigate the risk of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs) among patients with psoriasis in a large population.

Patients and methods

In this population-based study using the collaborative electronic health record research network, the risk of developing AAVs (ie, eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA)) was analyzed in a cohort of patients diagnosed with psoriasis between 2006 and 2024. Non-psoriasis controls were selected in a 1:1 ratio using propensity score matching. Patients who were diagnosed with AAVs before the index date were excluded. Univariate Cox proportional hazard model and subgroup analyses were used to estimate the hazard ratio (HR) with a 95% confidence interval (CI) for developing AAVs. The Kaplan-Meier method was used to plot the cumulative incidence curves. The risk of AAVs in psoriatic patients treated with biological agents was explored.

Results

After matching, 436,201 patients were included in each cohort. There were 281 incident cases of AAV during follow-up in the psoriasis cohort and 122 incident cases of AAV in the non-psoriasis cohort. The risk of developing AAVs in the psoriasis cohort was significantly higher than in the non-psoriasis cohort (HRs (95% CI) for AAVs, EGPA, and GPA were 2.01 (1.63 to 2.49), 1.84 (1.11 to 3.06), and 2.11 (1.65 to 2.71), respectively. Compared with psoriasis patients who did not receive biologics, those treated with biologics showed no statistically significant increase in AAVs risk (HR 1.31, 95% CI 0.65 to 2.66).

Conclusion

Patients with psoriasis have a higher risk of AAVs development. Treatment with biologic agents is not associated with an elevated risk of AAVs.

Weiterlesen

]]>251Fri, 10 Oct 2025 06:15:28 +0000Serum SCCA as a biomarker for assessing severity and monitoring treatment response in psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/serum-scca-as-a-biomarker-for-assessing-severity-and-monitoring-treatment-response-in-psoriasis-r250/BackgroundWhile clinical examination remains the diagnostic cornerstone for psoriasis, there is a relative lack of objective, quantitative biomarkers to complement clinical assessment for tracking disease severity and monitoring therapeutic response. We evaluated serum SCCA's utility in identifying psoriasis and assessing its severity across demographic (gender, age) and clinical (comorbidity) subgroups, and its association with therapeutic responses.

Methods

A total of 181 adult (≥18 years old) patients with newly diagnosed psoriasis were included in the disease group; 385 patients with other skin-related diseases and 658 healthy adults were included as controls. Patients diagnosed with tumors or renal failure were excluded. Serum SCCA was determined using Roche Cobas e 801 analyzer (Roche, Basel, Switzerland). Dynamic analysis was performed to evaluate the significance of serum SCCA in monitoring psoriasis treatment response.

Results

Serum SCCA levels in psoriasis patients were mainly affected by gender and concomitant diseases. Notably, SCCA demonstrated high diagnostic accuracy (AUC: 0.89-0.90) in patients with comorbidities, with sex-specific cutoffs. The cutoff value of serum SCCA for identifying severe psoriasis was 2.64 ng/mL with an AUC greater than 0.9 and an NPV over 95 %. Serum SCCA levels were significantly correlated with the psoriasis area and severity index (PASI) and body surface area (BSA) both before and after treatment. The median decrease rate of serum SCCA was close to 50 % at >5 days post-treatment and 60 % at >10 days post-treatment.

Conclusions

Serum SCCA shows promise as a reliable, complementary biomarker for the severity assessment and treatment monitoring of psoriasis. Its application for identification purposes should be stratified by sex and comorbidities.

Weiterlesen

]]>250Fri, 10 Oct 2025 06:15:28 +0000Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.https://www.psoriasis-news.de/articles.html/1_articles/bimekizumab-efficacy-in-psoriasis-by-subgroups-post-hoc-analysis-of-phase%C2%A033b-clinical-trials-r249/IntroductionPatient demographics, disease characteristics, and treatment history can impact the efficacy of biologic treatments in patients with psoriasis. Understanding the efficacy of biologics, such as bimekizumab, across diverse patient subgroups is important for optimising treatment outcomes. Here, we assess whether high overall clinical responses observed in bimekizumab-treated patients with moderate to severe plaque psoriasis are consistent across subgroups, both versus comparators and with long-term treatment.

Methods

Data were analysed post hoc from the BE SURE, BE VIVID, and BE READY phase 3 trials, their open-label extension (OLE) BE BRIGHT, and the BE RADIANT phase 3b trial. Patients received either bimekizumab or adalimumab to week 24 (BE SURE), bimekizumab or ustekinumab to week 52 (BE VIVID), and bimekizumab or secukinumab to week 48 (BE RADIANT). In the 3-year pooled analysis (all trials), included patients received bimekizumab continuously from baseline into the OLE. Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index > 0), and prior biologic exposure, at baseline. The proportions of patients achieving complete skin clearance (PASI 100; 100% improvement from baseline in Psoriasis Area and Severity Index) in each subgroup are reported alongside 95% confidence intervals (CI). Modified non-responder imputation (mNRI) was used for missing data.

Results

Following comparator-controlled periods, the proportion of bimekizumab-treated patients who achieved PASI 100 was consistent across subgroups and numerically greater versus patients who received adalimumab (to week 24), ustekinumab (to week 52), and secukinumab (to week 48) in all subgroups. Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to < 65 years]-73.7% [≥ 65 years]), sex (69.6% [male]-71.4% [female]), weight (63.4% [≥ 103.9 kg]-75.5% [< 74.3 kg]), disease duration (65.5% [≤ 5 years]-71.1% [> 20 years]), disease severity (67.7% [PASI 12 to < 15]-71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups.

Conclusion

Bimekizumab demonstrated consistently high long-term efficacy in patients with psoriasis across diverse subgroups. Higher rates of PASI 100 were achieved with bimekizumab versus adalimumab, ustekinumab, and secukinumab, across all subgroups. These results highlight bimekizumab as an effective treatment for a broad range of people living with psoriasis.

Trial registration

NCT03412747, NCT03370133, NCT03410992, NCT03598790, NCT03536884.

Weiterlesen

]]>249Fri, 10 Oct 2025 06:15:28 +0000Interleukin-1 Receptor Antagonist as a Potential Mediator Linking Psoriasis and Non-Alcoholic Fatty Liver Disease: Insights From Mendelian Randomization and Experimental Evidence.https://www.psoriasis-news.de/articles.html/1_articles/interleukin-1-receptor-antagonist-as-a-potential-mediator-linking-psoriasis-and-non-alcoholic-fatty-liver-disease-insights-from-mendelian-randomization-and-experimental-evidence-r248/BackgroundEpidemiological studies have revealed a close association between psoriasis and non-alcoholic fatty liver disease (NAFLD), but the causal relationship and underlying mechanisms remain unclear.

Materials and methods

In this study, we used genome-wide association study (GWAS) data from the MRC Integrative Epidemiology Unit (MRC-IEU) to investigate the causal relationship between psoriasis and NAFLD, as well as potential mediators. Two-sample and two-step MR analyses were conducted, followed by bulk and single-cell transcriptomic analyses to validate our MR findings. In vivo validation was performed using Enzyme-Linked Immunosorbent Assay (Sample of patients (n=10)), immunohistochemistry, and liver bulk transcriptomic analysis.

Results

The two-sample MR analysis revealed that genetically predicted psoriasis significantly increased the risk of NAFLD (OR = 1.07, 95% CI = 1.03-1.12, p = 0.001). Mediation analysis suggested that psoriasis was associated with elevated plasma Interleukin-1 receptor antagonist protein (IL-1RA) levels (OR = 1.02, 95% CI = 1.00-1.05, p = 0.031), which in turn raised the risk of NAFLD (OR = 1.15, 95% CI = 1.04-1.27, p = 0.006). In vivo experiments demonstrated elevated IL-1RA levels in the skin and plasma of psoriasis patients. Similarly, imiquimod (IMQ)-induced psoriasis mouse models exhibited increased IL-1RA levels in plasma and liver, accompanied by liver inflammation. MR and colocalization analysis indicated a positive correlation between IL-1RA, apolipoprotein B, and cholesterol.

Conclusion

Our study demonstrates that genetically predicted psoriasis increases the risk of NAFLD, and plasma IL-1RA may serve as a potential mediator between psoriasis and NAFLD.

Weiterlesen

]]>248Fri, 10 Oct 2025 06:15:28 +0000Psoriasis and phenotypic age acceleration in relation to all-cause and cardiovascular disease mortality risks in US adults.https://www.psoriasis-news.de/articles.html/1_articles/psoriasis-and-phenotypic-age-acceleration-in-relation-to-all-cause-and-cardiovascular-disease-mortality-risks-in-us-adults-r247/BackgroundPsoriasis is a chronic, immune-mediated inflammatory dermatosis associated with an elevated risk of cardiovascular disease (CVD) due to systemic inflammation and metabolic dysregulation. Phenotypic age acceleration (PhenoAge-accel) quantifies accelerated biological aging by comparing an individual's predicted 'phenotypic age' (based on immune/inflammatory markers and chronological age) to their actual age. Notably, both the onset and progression of psoriasis exhibit strong associations with biological aging process. The aim of this study was to investigate their combined effect on the risk of all-cause and CVD mortality.

Methods

This study included 11,443 participants from the National Health and Nutrition Examination Survey (NHANES) conducted during 2003-2006 and 2009-2010. Weighted multivariable logistic regression models were used to evaluate the association between PhenoAge-accel and psoriasis risk. PhenoAge-accel ≥ 0 was defined as PhenoAge-accel+. Furthermore, participants were stratified into four groups: psoriasis-/PhenoAge-accel-, psoriasis+/PhenoAge-accel-, psoriasis-/PhenoAge-accel+, and psoriasis+/PhenoAge-accel+. The Cox proportional hazards models were employed to investigate the joint effects of psoriasis and PhenoAge-accel on all-cause and CVD mortality risk.

Results

At baseline, 312 participants were diagnosed with psoriasis. After adjusting for covariates, compared to those with PhenoAge-accel < 0, the odds ratios (95% CI) for psoriasis in the PhenoAge-accel ≥ 0 group was 1.83 (1.36-2.45). During a median follow-up of 10.91 years (interquartile range: 9.83-14.75), 1059 deaths event occurred, including 306 caused by CVD. In the multivariable-adjusted model, compared with the reference group, the hazard ratios and 95% CIs for all-cause mortality in the psoriasis-/PhenoAge-accel+, psoriasis+/PhenoAge-accel-, and psoriasis+/PhenoAge-accel+ groups were 1.80 (1.54-2.10), 0.96 (0.56-1.65), and 2.70 (1.66-4.39), respectively. A similar trend was observed for CVD mortality.

Conclusions

PhenoAge-accel is positively associated with psoriasis risk. Furthermore, the coexistence of psoriasis and PhenoAge-accel are significantly associated with an increased risk of all-cause and CVD mortality.

Weiterlesen

]]>247Fri, 10 Oct 2025 06:15:28 +0000Overexpression of miR-718 in Keratinocytes Affects the Psoriatic Inflammation via Targeting STAT1: In Vitro and In Vivo Evidence.https://www.psoriasis-news.de/articles.html/1_articles/overexpression-of-mir-718-in-keratinocytes-affects-the-psoriatic-inflammation-via-targeting-stat1-in%C2%A0vitro-and-in%C2%A0vivo-evidence-r246/Weiterlesen

]]>246Fri, 10 Oct 2025 06:15:28 +0000SLPI controls neutrophil migration abilities and impacts neutrophil skin infiltration in experimental psoriasishttps://www.psoriasis-news.de/articles.html/1_articles/slpi-controls-neutrophil-migration-abilities-and-impacts-neutrophil-skin-infiltration-in-experimental-psoriasis-r245/Weiterlesen

]]>245Fri, 10 Oct 2025 06:15:28 +0000G-CSF Mediates Increased Renal Neutrophils and Kidney Damage in a Psoriasis Mouse Model.https://www.psoriasis-news.de/articles.html/1_articles/g-csf-mediates-increased-renal-neutrophils-and-kidney-damage-in-a-psoriasis-mouse-model-r243/Weiterlesen

]]>243Thu, 04 Sep 2025 18:54:24 +0000Spleen granulopoiesis in psoriasis immune microenvironment aggravates psoriasis via IL-6/P-STAT3 signaling.https://www.psoriasis-news.de/articles.html/1_articles/spleen-granulopoiesis-in-psoriasis-immune-microenvironment-aggravates-psoriasis-via-il-6p-stat3-signaling-r242/BackgroundPsoriasis is an immune-mediated chronic inflammatory condition characterized by significant neutrophil infiltration in the skin. Given that the spleen is the largest peripheral immune organ in the body, it is important to investigate whether it has any impact on skin inflammation in psoriasis.

Methods

To investigate this mechanism, a psoriatic mouse model was established by IMQ application. Flow cytometry and immunohistochemistry analyses were performed to determine the percentage of various immune cells in the spleen. The role of neutrophils was specifically assessed using the anti-Gr-1 antibody. Splenic granulopoiesis was evaluated using EdU labeling. To understand the spleen's role in skin inflammation, splenectomy was performed on the experimental mice. IL-6 levels were measured by ELISA, and P-STAT3 in neutrophils was detected via immunofluorescence. Further examination of IL-6's effects on neutrophil formation involved treating mice with IL-6 antibody. The severity of psoriasis was evaluated through histological staining and PASI scoring.

Results

Our study revealed that the spleens of psoriatic mice were enlarged compared to those of vehicle mice. Among immune cell populations, neutrophils showed the most significant changes, with marked increases in both spleen and skin of psoriatic mice and patients, contributing to disease progression. Post-splenectomy, neutrophil infiltration in the skin was reduced by approximately 60% in psoriatic mice. This indicates that the neutrophils in the skin were primarily derived from the spleen. Additionally, the spleen showed a notable capacity for granulopoiesis with elevated neutrophils. Moreover, we found elevated IL-6 levels in the skin, blood, and spleen in the model, which was decreased after splenectomy. Treatment with an IL-6 antibody reduced neutrophil formation in both the spleen and skin, which alleviated skin inflammation in psoriatic mice. Additionally, P-STAT3 signaling was decreased following IL-6 antibody treatment. The neutrophil infiltration in spleen and skin was decreased after injection with the inhibitor of P-STAT3, which also alleviated the inflammation of psoriatic model. Thus, IL-6 served as the dominant regulator of spleen granulopoiesis, a process potentially mediated by P-STAT3 signaling.

Conclusions

The spleen plays a crucial role in the immune microenvironment of psoriasis as a major site of granulopoiesis, influencing neutrophil infiltration in the skin of psoriatic mice. Additionally, IL-6 is a key regulator of neutrophil formation in the spleen of psoriatic mice, likely through P-STAT3-dependent mechanisms.

Weiterlesen

]]>242Thu, 04 Sep 2025 18:54:24 +0000A systematic review of novel Phosphodiesterase-4 inhibitors in the treatment of psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/a-systematic-review-of-novel-phosphodiesterase-4-inhibitors-in-the-treatment-of-psoriasis-r241/BackgroundPsoriasis is a chronic immune-mediated skin disease that significantly impacts patients' quality of life due to its physical, psychological, and systemic burden. Phosphodiesterase-4 (PDE-4) plays a pivotal role in the inflammatory cascade of the disease through the modulation of intracellular cyclic adenosine monophosphate (cAMP) levels. This systematic review evaluates current evidence on the clinical efficacy and safety of novel PDE-4 inhibitors in the treatment of psoriasis.

Methods

A systematic search was conducted in PubMed/Medline, Ovid Embase, and Web of Science databases through January 18th, 2025, to identify clinical studies evaluating PDE-4 inhibitors in patients with psoriasis. Methodological quality and risk of bias were assessed using the National Institutes of Health (NIH) quality assessment tool and the Murad et al.quality assessment tool.

Results

Out of 1,942 related studies, twelve studies with 642 patients met our inclusion criteria. Among oral PDE-4 inhibitors, oral roflumilast demonstrated consistent improvements in the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI), as well as patient-reported outcomes, in cases with moderate to severe plaque psoriasis. Gastrointestinal symptoms were the most common adverse events. Similarly, orismilast and ME3183 also demonstrated significant PASI reductions and favorable tolerability, while topical agents like crisaborole and PF-07038124 showed a rapid localized response in patients suffering from mild to moderate psoriasis, with minimal adverse effects in sensitive areas, including the face and intertriginous regions.

Conclusion

PDE-4 inhibitors, both oral and topical, demonstrate promising efficacy and acceptable safety profiles in the treatment of psoriasis. To confirm their long-term benefits and improve clinical use, larger-scale studies with longer follow-up and a wider range of patients are required.

Weiterlesen

]]>241Thu, 04 Sep 2025 18:54:24 +0000Association Between Alcohol Consumption and Psoriasis: Exploratory Analysis of Crowdsourced Web Search Data in Sweden.https://www.psoriasis-news.de/articles.html/1_articles/association-between-alcohol-consumption-and-psoriasis-exploratory-analysis-of-crowdsourced-web-search-data-in-sweden-r240/BackgroundThe nature of the relationship between psoriasis and alcohol consumption has been the topic of discussion for many years. Some studies have found that a higher intake of alcohol may be associated with a more severe manifestation of the disease. At the same time, patients with psoriasis often demonstrate elevated levels of alcohol consumption. It has not yet been fully established whether alcohol abuse serves as a trigger for psoriasis or if patients with psoriasis are simultaneously more prone to alcohol abuse.

Objective

The objective of this study was to employ Google Trends as a tool for crowdsourcing data on a national level to explore the relationship between psoriasis and the consumption of alcohol in Sweden.

Methods

This study examines crowdsourced web search data related to psoriasis and other skin disease-related search terms (such as utslag [rash]) as well as search interest in different types of alcohol. The analysis covers a 5-year period from 2018 to 2023 in Sweden, focusing on search behavior and correlations across this period.

Results

The search behavior regarding psoriasis and alcohol-related search terms showed seasonal variations throughout the year. The relative search volume for psoriasis peaked in February, while alcohol-related searches, particularly Systembolaget and vodka, peaked in December and June. Our statistical analysis revealed relationships between the search interest regarding psoriasis and terms related to alcohol consumption, with disparities between different types of alcohol. The term "psoriasis" was negatively correlated with "Systembolaget" (r=-0.210), "vitt vin" (r=-0.224), and "vodka" (r=-0.220) (all P<.001), while the term "utslag" showed positive correlations with these same alcohol-related terms (r=0.278-0.347; P<.001).

Conclusions

Crowdsourced data can offer valuable insights into population-level behavior. The observed negative correlations between psoriasis and alcohol-related searches suggest complex interactions, possibly reflecting reduced disease awareness or care during periods of higher alcohol consumption. The direction and strength of the correlations with psoriasis were not consistent across the different types of alcohol investigated in this study, which poses the question whether the relationship might be influenced by the type of beverage consumed. Further research is warranted to explore underlying mechanisms and validate these findings in clinical populations.

Weiterlesen

]]>240Thu, 04 Sep 2025 18:54:24 +0000Smilax glabra Roxb. extract alleviates psoriasis-like lesions in mice by the synergistic effects of TOP2A inhibition and AhR activation.https://www.psoriasis-news.de/articles.html/1_articles/smilax-glabra-roxb-extract-alleviates-psoriasis-like-lesions-in-mice-by-the-synergistic-effects-of-top2a-inhibition-and-ahr-activation-r239/Weiterlesen

]]>239Thu, 04 Sep 2025 18:54:24 +0000Epidemiology of Hypertension in Psoriasis: An Analysis of Trends from 2006 to 2023.https://www.psoriasis-news.de/articles.html/1_articles/epidemiology-of-hypertension-in-psoriasis-an-analysis-of-trends-from-2006-to-2023-r238/Weiterlesen

]]>238Thu, 04 Sep 2025 18:54:24 +0000Patient Experiences with Psoriatic Disease in the USA: Results from the Psoriasis and Beyond Global Study.https://www.psoriasis-news.de/articles.html/1_articles/patient-experiences-with-psoriatic-disease-in-the-usa-results-from-the-psoriasis-and-beyond-global-study-r237/BackgroundPsoriatic disease (PsD) is a chronic, multisystem, inflammatory disorder encompassing psoriasis, psoriatic arthritis (PsA), and their associated comorbidities.

Objective

The aim of this subanalysis of the global "Psoriasis and Beyond" study was to evaluate patients' experiences of living with PsD in the USA.

Methods

The study included a cross-sectional, quantitative, 25-min online survey of adults with self-reported, healthcare professional-diagnosed, moderate-to-severe psoriasis, with or without PsA. USA-based patients were recruited through online panels by the Institut de Publique Sondage D'Opinion Secteur and The National Psoriasis Foundation.

Results

This analysis included 793 US patients with psoriasis; 43% also had PsA. Overall, 75% of patients knew that their disease was systemic, and 65% had heard the term "psoriatic disease." Of patients without diagnosed PsA, 50% screened positive for PsA using the Psoriasis Epidemiology Screening Tool. Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively). Overall, 29% of patients reported that they could not work or study in the week prior to the survey; of these, 98% responded that psoriasis had a very or extremely large impact on their QoL. Mean diagnostic delays of 3.7 and 3.3 years for psoriasis and PsA, respectively, were reported.

Conclusions

This analysis of USA-based patients with PsD highlights the profound impact of PsD on emotional well-being and QoL and suggests potential underdiagnosis of PsA. There is a need to ensure early PsD diagnosis and to provide holistic treatment, including mental health support.

Weiterlesen

]]>237Thu, 04 Sep 2025 18:54:24 +0000Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis.https://www.psoriasis-news.de/articles.html/1_articles/incidence-and-predictors-of-secondary-failure-to-biologic-therapy-in-patients-with-psoriatic-arthritis-r236/ObjectiveSecondary failure to biologic DMARDs (bDMARDs) is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). We aimed to define the frequency and incidence of this phenomenon in PsA and identify the risk factors for its occurrence.

Methods

We retrieved data on PsA patients from our single-centre, specialized-care, prospective observational cohort who initiated and remained on bDMARDs for ≥1 year after clinic enrollment between 2000 and 2023. We defined response to therapy at the one-year visit (baseline) as achievement of ≥40% reduction in the swollen joint count (SJC) and either ≥50% reduction in PASI or PASI ≤2. We defined secondary failure as the inability to maintain response criteria or as the clinician's judgment of loss of effectiveness. To examine factors associated with secondary failure, we fitted Cox regression models.

Results

Of 482 patients included in the study, 264 (54.8%) were responders at one year. Of these, 94 (35.6%) developed secondary failure at a median of 1.6 [IQR: 0.7, 3.8] years from response. In the multivariable model, higher SJC (HR 1.39, 95% CI 1.05-1.84) and PASI (HR 1.14, 95% CI 1.01-1.29) at baseline were associated with secondary failure. TNFi vs. other bDMARD use (HR 0.39, 95% CI 0.18-0.88), initiation as first-line bDMARD (HR 0.48, 95% CI 0.25-0.91), and treatment initiation during more recent calendar years (HR 0.34, 95% CI 0.12-0.98) were associated with less secondary failure.

Conclusion

Secondary failure to bDMARDs is common in PsA and may be influenced by both disease- and therapy-related factors.

Weiterlesen

]]>236Thu, 04 Sep 2025 18:54:24 +0000GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study.https://www.psoriasis-news.de/articles.html/1_articles/glp-1ra-and-reduced-mortality-cardiovascular-and-psychiatric-risks-in-psoriasis-a-large-scale-cohort-study-r235/BackgroundPsoriasis is associated with a significant comorbidity burden, especially cardiovascular and metabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RA), such as semaglutide, used to treat obesity and diabetes, could potentially reduce comorbidity in patients with psoriasis.

Objective

To investigate all-cause mortality, cardiovascular, inflammatory, psychiatric outcomes, and adverse events in psoriasis patients treated with GLP-1RA.

Methods

This retrospective population-based cohort study utilized real-world data from the US TriNetX database. Patients with psoriasis who were treated for diabetes or obesity with GLP-1RA during the full follow-up period of 2 years were compared with those treated with other systemic anti-diabetic or obesity drugs. After 1:1 propensity-score matching for relevant risk factors, 3,048 participants were included in each cohort. The primary outcomes included the risk of cardiometabolic, psychiatric, and autoimmune sequelae of psoriasis, as well as all-cause mortality and potential adverse drug events. The analysis was repeated using cohorts without psoriasis and results were further validated through two sensitivity analyses involving (i) later follow-up periods, or (ii) exclusion of patients with pustular psoriasis.

Results

In the matched cohorts of 3,048 patients with psoriasis treated with GLP-1RA (60.37% females, mean age 56.94 years, standard deviation [SD] 12.02 years) versus other antidiabetic and obesity drugs (61.91% females, mean age 56.42 years, SD 14.16 years), GLP-1RA treatment was associated with significantly decreased all-cause mortality (hazard ratio [HR] 0.219, 95% confidence interval [CI] 0.123-0.391, p<0.0001) and reduced risk for major adverse cardiac events (MACE, HR 0.561, 95% CI 0.442-0.714, p<0.0001). Additionally, lower risks for alcohol (HR 0.346, CI 0.174-0.685, p=0.009) and substance abuse (HR 0.510, CI 0.350-0.743, p=0.002) were observed. Typical adverse drug events were not more frequent in the GLP-1RA cohort. The risk reductions were more pronounced in the cohorts with psoriasis compared to persons with obesity or diabetes without psoriasis. Findings were consistent across all sensitivity analyses.

Conclusions

GLP-1RA treatment was safe and associated with reduced risks of cardiovascular and psychiatric comorbidities, as well as lower mortality in patients with psoriasis, with risk reductions markedly higher than in cohorts without psoriasis. Physicians should consider this drug class for patients with psoriasis and comorbid obesity or diabetes.

Weiterlesen

]]>235Thu, 04 Sep 2025 18:54:24 +0000Platelet Activation and a Platelet Biosignature Are Associated With Cardiovascular Risk in Patients With Controlled Psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/platelet-activation-and-a-platelet-biosignature-are-associated-with-cardiovascular-risk-in-patients-with-controlled-psoriasis-r234/Weiterlesen

]]>234Thu, 04 Sep 2025 18:54:24 +0000Does ultrasound detect joint and intestinal changes in psoriatic arthritis and ulcerative colitis after immunobiological treatment: A case reporthttps://www.psoriasis-news.de/articles.html/1_articles/does-ultrasound-detect-joint-and-intestinal-changes-in-psoriatic-arthritis-and-ulcerative-colitis-after-immunobiological-treatment-a-case-report-r233/No abstract supplied.

Weiterlesen

]]>233Wed, 03 Sep 2025 07:11:26 +0000Leveraging Pixel-wise Embeddings for Segmenting Psoriasis Lesion Areashttps://www.psoriasis-news.de/articles.html/1_articles/leveraging-pixel-wise-embeddings-for-segmenting-psoriasis-lesion-areas-r232/In the context of psoriasis lesion segmentation, traditional methods in image segmentation, including region-based approaches like Mask R-CNN, have shown notable success. However, the problem of segmenting irregular and intricate biological structures such as psoriasis lesions presents significant challenges that cannot be effectively captured by standard bounding box approximations. This paper explores the potential of transforming psoriasis lesion segmentation into pixel labeling tasks, which promise greater efficiency and integration with modern image-to-image networks widely used across various domains. We investigate the limitations of convolutional-based architectures in generating dense pixel embeddings capable of distinguishing individual lesions. Through both theoretical analysis and empirical evidence, we propose a novel approach that leverages semi-convolutional operations. These modifications, which introduce spatially guided pixel embeddings, offer substantial improvements over traditional methods and demonstrate their applicability to the segmentation of complex biological forms. By drawing connections to advanced techniques such as Hough voting and bilateral kernels steered by convolutional networks, we show that these methods significantly enhance the segmentation accuracy of psoriasis lesions, outperforming conventional region-based models like Mask R-CNN in terms of precision and adaptability to irregular shapes.

Weiterlesen

]]>232Wed, 03 Sep 2025 07:11:26 +0000The role of psychological stress in the pathogenesis of psoriasis.https://www.psoriasis-news.de/articles.html/1_articles/the-role-of-psychological-stress-in-the-pathogenesis-of-psoriasis-r231/Weiterlesen

]]>231Wed, 03 Sep 2025 07:11:26 +0000Development and Validation of an Artificial Intelligence-Driven Model for Accurate Classification of Erythrodermic Psoriasis Severity: Erythrodermic Psoriasis Integrated Classification System (EPICS).https://www.psoriasis-news.de/articles.html/1_articles/development-and-validation-of-an-artificial-intelligence-driven-model-for-accurate-classification-of-erythrodermic-psoriasis-severity-erythrodermic-psoriasis-integrated-classification-system-epics-r230/Weiterlesen

]]>230Wed, 03 Sep 2025 07:11:26 +0000